A cosmetic composition is provided, which comprises a carrier and a Vetiver root extract, in particular an extract from exhausted Vetiver root. This composition provides a stimulation of sebum production, stimulation of sebum antimicrobial, lipids production, activation of adipocytes volume increase, skin hydration, skin tonicity booster, skin fatigue reduction, perilabial wrinkles reduction, skin replumping, and fragrance long-lastingness enhancement.

A cosmetic composition is provided, which comprises a carrier and a Vetiver root extract, in particular an extract from exhausted Vetiver root. This composition provides a stimulation of sebum production, stimulation of sebum antimicrobial, lipids production, activation of adipocytes volume increase, skin hydration, skin tonicity booster, skin fatigue reduction, perilabial wrinkles reduction, skin replumping, and fragrance long-lastingness enhancement.

The invention discloses the medicinal use of kaurene compound in the prevention and treatment of sepsis, systemic inflammatory response syndrome (SIRS) and multiple organ failure caused by sepsis, including acute pulmonary failure, acute heart failure and renal failure.

The invention relates to a method of separation by fractionalization of the antioxidant active ingredients of Rosemary plant, which are the diterpenes Carnosic acid and Camosol and the phenolic acid Rosmarinic Acid, through column chromatography method. The production process involves the passage of rosemary extract, which is obtained in/with a proper solvent, through a column packed with a suitable packing material, the separation of the part rich in carnosic acid and carnosol, and the obtainment of a deodorized product in powder form after drying. During the process, another extract containing rosmarinic acid with high antioxidant activity is also obtained. The invention thus allows the use of an extract rich in carnosic acid and carnosol and another extract containing rosmarinic acid—which are obtained at once with no need for additional processes like acidification, precipitation, membrane filtration or deodorization—in food, pharmaceutical and cosmetic sector applications.

The invention relates to a method of separation by fractionalization of the antioxidant active ingredients of Rosemary plant, which are the diterpenes Carnosic acid and Camosol and the phenolic acid Rosmarinic Acid, through column chromatography method. The production process involves the passage of rosemary extract, which is obtained in/with a proper solvent, through a column packed with a suitable packing material, the separation of the part rich in carnosic acid and carnosol, and the obtainment of a deodorized product in powder form after drying. During the process, another extract containing rosmarinic acid with high antioxidant activity is also obtained. The invention thus allows the use of an extract rich in carnosic acid and carnosol and another extract containing rosmarinic acid—which are obtained at once with no need for additional processes like acidification, precipitation, membrane filtration or deodorization—in food, pharmaceutical and cosmetic sector applications.

The present invention relates generally to a rosemary plant and, more specifically, to a proprietary clonal plant line KI937 that hyper-accumulates carnosic acid.

The present invention relates generally to a rosemary plant and, more specifically, to a proprietary clonal plant line KI937 that hyper-accumulates carnosic acid.

The present invention relates to pharmaceutical compositions containing steviol glycoside and or steviol glycoside derivatives as well as to their use as osmotics in particular for use in the treatment of chronic renal failure by dialysis.

Compounds of formula (I):

##STR00001##

where R.sup.1, R.sup.2, R.sup.3, R.sup.4a, R.sup.4b, R.sup.5, R.sup.6 and R.sup.7 are defined herein, or stereoisomers or pharmaceutically acceptable salts thereof, are described herein. Such compounds have activity as SHIP1 modulators, and thus may be used to treat any of a variety of diseases, disorders or conditions that would benefit from SHIP1 modulation. Compositions comprising a compound of formula (I) in combination with a pharmaceutically acceptable carrier or diluent are also disclosed, as are methods of SHIP1 modulation by administration of such compounds to an animal in need thereof.

A pharmaceutical composition and method for regenerating cardiomyocytes in treating or repairing heart muscle damages cause by an ischemic disease. The pharmaceutical composition contains an active ingredient compound with a backbone structure of Formula (I). The active ingredient compound is capable of (a) increasing viability of myogenic precursor cells to enable said precursor cells to survive through an absolute ischemic period; (b) reconstituting a damaged blood supply network in said heart region where said injured muscle is located; and (c) enhancing cardiomyogenic differentiation efficiency of said precursor cells down cardiac linage, said steps being performed simultaneously or in any particular order.